A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA)

Vaccine

Volumn 32, Issue 23, 2014, Pages 2688-2695

  Koeberling, Oliver ^a   Ispasanie, Emma ^b,c   Hauser, Julia ^b,c   Rossi, Omar ^a   Pluschke, Gerd ^b,c   Caugant, Dominique A ^d   Saul, Allan ^a   MacLennan, Calman A ^a,e  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Factor H binding protein; GMMA; Meningitis; Meningococcus; Neisseria meningitidis; Outer membrane vesicles; Vaccine

Indexed keywords

BACTERIUM ANTIBODY; INTERLEUKIN 6; MENINGOCOCCUS VACCINE; TOLL LIKE RECEPTOR 4;

AFRICA SOUTH OF THE SAHARA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPIDEMIC MENINGITIS; FEMALE; GENE LOCUS; HUMAN; HUMAN CELL; INFECTION PREVENTION; KIDNEY CELL; MENINGOCOCCOSIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

FACTOR H BINDING PROTEIN; GMMA; MENINGITIS; MENINGOCOCCUS; NEISSERIA MENINGITIDIS; OUTER MEMBRANE VESICLES; VACCINE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; FEMALE; GENE KNOCKOUT TECHNIQUES; GENETIC ENGINEERING; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS, SEROGROUP W-135; SERUM BACTERICIDAL ANTIBODY ASSAY;

EID: 84899941194     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.068     Document Type: Article

References (40)

1. Halperin S.A., Bettinger J.A., Greenwood B., Harrison L.H., Jelfs J., Ladhani S.N., et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012, 30(Suppl. 2):B26-B36.
2. Laforce F.M., Okwo-Bele J.M. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011, 30:1049-1057.
3. Xie O., Pollard A.J., Mueller J.E., Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine 2013, 31:2852-2861.
4. Collard J.M., Maman Z., Yacouba H., Djibo S., Nicolas P., Jusot J.F., et al. Increase in Neisseria meningitidis serogroup W135, Niger, 2010. Emerg Infect Dis 2010, 16:1496-1498.
5. Delrieu I., Yaro S., Tamekloe T.A., Njanpop-Lafourcade B.M., Tall H., Jaillard P., et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 2011, 6:e19513.
6. Marc L.F., Ravenscroft N., Djingarey M., Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009, 27(Suppl. 2):B13-B19.
7. Daugla D.M., Gami J.P., Gamougam K., Naibei N., Mbainadji L., Narbe M., et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 2014, 383:40-47.
8. Kristiansen P.A., Ba A.K., Sanou I., Ouedraogo A.S., Ouedraogo R., Sangare L., et al. Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine. BMC Infect Dis 2013, 13:363.
9. Kristiansen P.A., Diomande F., Ba A.K., Sanou I., Ouedraogo A.S., Ouedraogo R., et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013, 56:354-363.
10. Berlanda S.F., Colucci A.M., Maggiore L., Sanzone S., Rossi O., Ferlenghi I., et al. High yield production process for Shigella outer membrane particles. PLoS One 2012, 7:e35616.
11. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197:789-799.
12. Beernink P.T., Granoff D.M. The modular architecture of meningococcal factor H-binding protein. Microbiology 2009, 155:2873-2883.
13. Pajon R., Beernink P.T., Harrison L.H., Granoff D.M. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010, 28:2122-2129.
14. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999, 281:1520-1527.
15. Pajon R., Fergus A.M., Koeberling O., Caugant D.A., Granoff D.M. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 2011, 5:e1302.
16. Huber C.A., Pfluger V., Hamid A.W., Forgor A.A., Hodgson A., Sie A., et al. Lack of antigenic diversification of major outer membrane proteins during clonal waves of Neisseria meningitidis serogroup A colonization and disease. Pathog Dis 2013, 67:4-10.
17. Ferrari G., Garaguso I., Adu-Bobie J., Doro F., Taddei A.R., Biolchi A., et al. Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics 2006, 6:1856-1866.
18. Berlanda S.F., Doro F., Rodriguez-Ortega M.J., Stella M., Liberatori S., Taddei A.R., et al. Proteomics characterization of outer membrane vesicles from the extraintestinal pathogenic Escherichia coli DeltatolR IHE3034 mutant. Mol Cell Proteomics 2008, 7:473-485.
19. Henry T., Pommier S., Journet L., Bernadac A., Gorvel J.P., Lloubes R. Improved methods for producing outer membrane vesicles in Gram-negative bacteria. Res Microbiol 2004, 155:437-446.
20. van de Waterbeemd B., Streefland M., van der Ley P., Zomer B., van D.H., Martens D., et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 2010, 28:4810-4816.
21. Grizot S., Buchanan S.K. Structure of the OmpA-like domain of RmpM from Neisseria meningitidis. Mol Microbiol 2004, 51:1027-1037.
22. Forgor A.A., Leimkugel J., Hodgson A., Bugri A., Dangy J.P., Gagneux S., et al. Emergence of W135 meningococcal meningitis in Ghana. Trop Med Int Health 2005, 10:1229-1234.
23. Ieva R., Alaimo C., Delany I., Spohn G., Rappuoli R., Scarlato V. CrgA is an inducible LysR-type regulator of Neisseria meningitidis, acting both as a repressor and as an activator of gene transcription. J Bacteriol 2005, 187:3421-3430.
24. Koeberling O., Seubert A., Granoff D.M. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 2008, 198:262-270.
25. Adu-Bobie J., Lupetti P., Brunelli B., Granoff D., Norais N., Ferrari G., et al. GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence. Infect Immun 2004, 72:1914-1919.
26. Hou V.C., Koeberling O., Welsch J.A., Granoff D.M. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 2005, 192:580-590.
27. Egen RC, Fortin LA, Sun WWQ. Animal component free meningococcal polysaccharide fermentation and seedbank development. Patent No. US 7,399,615 B2; 2008.
28. Beernink P.T., Shaughnessy J., Ram S., Granoff D.M. Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin Vaccine Immunol 2010, 17:1074-1078.
29. Massenet D., Inrombe J., Mevoula D.E., Nicolas P. Serogroup W135 meningococcal meningitis, Northern Cameroon, 2007-2008. Emerg Infect Dis 2009, 15:340-342.
30. Koumare B., Ouedraogo-Traore R., Sanou I., Yada A.A., Sow I., Lusamba P.S., et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 2007, 25(Suppl. 1):A37-A41.
31. Boisier P., Nicolas P., Djibo S., Taha M.K., Jeanne I., Mainassara H.B., et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007, 44:657-663.
32. Gagneux S.P., Hodgson A., Smith T.A., Wirth T., Ehrhard I., Morelli G., et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 2002, 185:618-626.
33. Zollinger W.D., Donets M.A., Schmiel D.H., Pinto V.B., Labrie J., Moran E.E. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 2010, 28:5057-5067.
34. Pajon R., Fergus A.M., Granoff D.M. Mutant native outer membrane vesicles combined with a serogroup A polysaccharide conjugate vaccine for prevention of meningococcal epidemics in Africa. PLoS One 2013, 8:e66536.
35. Koeberling O., Delany I., Granoff D.M. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol 2011, 18:736-742.
36. Koeberling O., Giuntini S., Seubert A., Granoff D.M. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 2009, 16:156-162.
37. Beernink P.T., Caugant D.A., Welsch J.A., Koeberling O., Granoff D.M. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 2009, 199:1360-1368.
38. Beernink P.T., Shaughnessy J., Braga E.M., Liu Q., Rice P.A., Ram S., et al. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 2011, 186:3606-3614.
39. Beernink P.T., Shaughnessy J., Pajon R., Braga E.M., Ram S., Granoff D.M. The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog 2012, 8:e1002688.
40. Vogel U., Weinberger A., Frank R., Muller A., Kohl J., Atkinson J.P., et al. Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis. Infect Immun 1997, 65:4022-4029.